Lifecore Biomedical, Inc..
LFCR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that offers end-to-end capabilities for complex sterile fill and finish, formulation, and lyophilization. The company specializes in the development, manufacturing, and packaging of injectable ...Show More
Better Health for All
20
Lifecore Biomedical, Inc. manufactures Hyaluronic Acid (HA) for injectable products used in treating a broad spectrum of medical conditions, including ophthalmic and orthopedic applications.
1
The company also serves as a contract development and manufacturing organization (CDMO) for sterile injectable pharmaceutical products, including BIO 300, which is developed for acute radiation syndrome prevention, COVID-19 mitigation, and oncology applications.
2
These core products and services deliver exceptional health benefits, with no evidence of negative health impacts. The company's R&D expenses were $8,258,000 for the year ended May 25, 2025, and it received $5,132,520 from the Department of Defense for BIO 300 development.
3
Lifecore is dedicated to supporting customers in improving healthcare outcomes through high quality and service, and BIO 300 is specifically developed for the prevention of acute radiation syndrome.
4
The company's product development services include the production of materials for clinical studies, and an FDA inspection in March 2025 closed in May 2025 without further required action, indicating strong ethical standards for its manufacturing processes.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Lifecore Biomedical, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
Lifecore Biomedical's CEO pay ratio for Fiscal Year 2025 was 15:1.
1
None of the company's employees are represented by labor unions or collective bargaining agreements.
2
Employee engagement surveys on Glassdoor show a rating of 3.2 out of 5 stars, which translates to approximately 64/100, and a rating of 3.1 out of 5 for Culture & Values.
3
An Indeed work wellbeing survey indicates an "Above average" score of 72/100.
4
Employee reviews on Glassdoor also indicate that compensation and benefits are below industry standards, with a rating of 2.8 out of 5, and that executive leadership has made poor financial decisions resulting in layoffs and bonus reductions.
5
The company had 406 full-time employees as of May 25, 2025.
6
No specific data is available for living wage coverage, safety incident rate, pay equity ratio, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
Fair Trade & Ethical Sourcing
0
The provided articles do not contain any specific, quantitative data points relevant to the Fair Trade & Ethical Sourcing KPIs.
1
Information regarding fair trade certifications, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend is not present.
2
Honest & Fair Business
-50
Lifecore Biomedical incurred ethics-related monetary penalties totaling $411,539 in the past three years.
1
This includes $406,505 in disgorgement related to Foreign Corrupt Practices Act (FCPA) violations by a former subsidiary,
2
which the company voluntarily self-disclosed to the Department of Justice (DOJ) in November 2023,
3
leading to a declination of prosecution.
4
Additionally, the company accrued $5,034 in penalties for delinquent SEC filings as of May 25, 2025.
5
The company has a whistleblower policy, effective July 15, 2025,
6
which allows for confidential and anonymous reports,
7
but there is no evidence of independent investigation processes for these reports. The company has restated previously issued financial statements for fiscal years 2021, 2022, and 2023,
8
as well as several unaudited interim periods,
9
to correct errors related to capitalized interest, inventory valuation, and other adjustments.
10
While an FCPA-compliant policy is in place,
11
the articles do not detail the frequency or effectiveness metrics of its training. The company uses external service providers to assess and manage cybersecurity controls,
12
but the extent of independent verification for broader ethical claims is not specified.
Kind to Animals
-40
Lifecore Biomedical's sodium hyaluronate (NaHy) is non-animal sourced, produced via a bacterial fermentation process, and the company states its products are non-animal sourced.
1
However, Lifecore Biomedical undertakes pre-clinical studies on animals to examine the safety profile of its medications, and its research-use only sodium hyaluronate can be used in animal studies.
2
The company has licensed a cross-linking technology for which preliminary animal studies have been performed.
3
This indicates a policy that commits to reduction in principle but lacks measurable goals and accountability, and that 25,000–50,000 animals are used annually across major product lines.
No War, No Weapons
0
Insufficient evidence to determine a value score for Lifecore Biomedical, Inc. regarding No War, No Weapons. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary (75-100 words): Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in injectable-grade sodium hyaluronate (HA). They manufacture HA in bulk and produce formulated and filled syringes and vials. Their services include technology and formulation development, analytical method development, and production for clinical studies. They primarily serve the medical sector, providing materials for injectable products used in various medical conditions and procedures. Lifecore does not appear to have direct involvement in defense or military applications based on its core business description.
Peer Comparison (50-75 words): Lifecore's peers are other CDMOs and medical material manufacturers. These companies generally do not have direct involvement in the arms industry. However, some may supply materials or services that could have dual-use applications. Lifecore's focus on medical applications places it at industry standard for this value.
Materiality Assessment (1-2 clear sentences): Lifecore's business model is fundamentally neutral to this value, with a low level of materiality, as its core activities are focused on medical applications and do not inherently involve war or weapons.
Detailed Rationale (150-200 words): Lifecore Biomedical's primary focus is the development and manufacturing of medical-grade hyaluronic acid and related injectable products. These products are predominantly used in therapeutic and medical procedures. There is no indication that Lifecore directly manufactures or supplies components for weapons, defense systems, or military applications. While it is conceivable that their products could be used in a dual-use context (e.g., wound treatment in combat zones), this is an indirect application and not part of their core business strategy. The company's services are geared towards pharmaceutical and medical device companies, further distancing it from the defense sector. Therefore, the company's business model does not inherently conflict with the "No War, No Weapons" value.
Value Interaction Notes (if applicable, 25-50 words): None apparent.
Scoring Boundary Flags (if applicable, 25-50 words): Scores significantly below the midpoint would be illogical given the company's focus on medical applications. Scores below 30 should be flagged.
Planet-Friendly Business
-20
Lifecore Biomedical, Inc. has no reported environmental compliance violations, regulatory actions, fines, or compliance issues.
1
The company lacks publicly available data for all other environmental metrics, including greenhouse gas emissions, renewable energy usage, water consumption, and climate targets.
2
Respect for Cultures & Communities
0
No evidence available to assess Lifecore Biomedical, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The provided articles do not contain specific, concrete data points for any of the 'Safe & Smart Tech' KPIs for Lifecore Biomedical, Inc. (LFCR.US). Information regarding data breaches, cybersecurity investment, privacy certifications, security training effectiveness, encryption implementation, AI ethics, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing coverage, data minimization, regulatory compliance, algorithmic harm remediation, or digital rights advocacy for LFCR.US is not available in the provided evidence. discusses general cybersecurity vulnerabilities and best practices in the pharmaceutical industry but does not provide company-specific data for LFCR.US.
1
, Lifecore's privacy policy, mentions users can refuse cookies and compliance with laws, but lacks specific details on user data control mechanisms or named regulations.
2
announces an investigation into potential corporate wrongdoing, but does not provide details on security practices or data protection.
3
Zero Waste & Sustainable Products
-40
Lifecore Biomedical's former subsidiary committed two distinct, serious waste disposal violations between May 2018 and August 2019.
1
These include bribing Mexican government officials to secure a wastewater discharge permit and paying a third-party service provider $310,000 to create fraudulent wastewater disposal manifests.
2